Resistance in P388 Leukaemia Cells Due to Bcl-X Overexpression
Author Information
Author(s): J-S Kuhl, S Krajewski, GE Duran, JC Reed, BI Sikic
Primary Institution: Stanford University School of Medicine
Hypothesis
The overexpression of the long form of the Bcl-X protein contributes to drug resistance in P388 leukaemia cells.
Conclusion
The study found that overexpression of Bcl-X-L in P388/SPR cells leads to broad cross-resistance to various cytotoxic agents.
Supporting Evidence
- Overexpression of Bcl-X-L was observed in P388/SPR cells.
- P388/SPR cells showed broad cross-resistance to various cytotoxic drugs.
- Transfection of Bcl-X-L into P388 cells conferred similar drug resistance.
- Apoptosis induction was significantly reduced in P388/SPR cells.
Takeaway
Some cancer cells can become resistant to treatments, and this study shows that a specific protein, Bcl-X-L, helps these cells survive against drugs.
Methodology
The study involved characterizing a resistant variant of murine P388 leukaemia cells and analyzing their drug resistance mechanisms through various assays.
Limitations
The study did not explore all potential mechanisms of resistance and focused primarily on Bcl-X-L expression.
Statistical Information
P-Value
p<0.005
Confidence Interval
95% confidence limits
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website